FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2476753326> ?p ?o ?g. }

• W2476753326 abstract "Abstract Objective Whetherinterferon alpha (IFN-α) has special therapeutic effect formyeloproliferative neoplasm (MPN) patients with JAK2V617F mutations was not widely confirmed. Our purpose was to evaluate the therapeutic effect of interferon alpha (IFN-α) in MPN patients with JAK2V617F mutations. Methods A total of 99 advanced MPN patients (including 68 polycythemia vera (PV) patients with 34 JAK2V617F mutations and 68 essential thrombocytosis (ET) with JAK2V617F mutations) patients) were enrolled to the study during 2007 to 2013 with informed consent, then they were divided into two groups: the IFN-α group (patients received a standard dose of IFN-α with (30-50)ug/d ) and the Hydroxyurea (HU) group (patients received a a dose of (0.25-0.5)g/d for HU). The progression-free survival rate were analyzed for a median of 32.0 (6.0 to 60.0) months follow-up period. Results The overall response rate between IFN-α and Hydroxyurea therapy groups of essential thrombocytosis (ET) patients with JAK2V617F mutations had no significant difference (88.2% vs 85.0%, P>0.05), but the 5-year progression-free survival rate of two groups showed significant difference (88.2% vs 55.0%, P<0.05). The overall response rate (78.6% vs 82.4% ) and 5-year progression-free survival rate (57.1% vs 58.8%) between IFN-α and Hydroxyurea therapy groups of ET patients without JAK2V617F mutations had no significant difference (P>0.05). The overall response rate between IFN-α and Hydroxyurea therapy groups of polycythemia vera (PV) patients with JAK2V617F mutations had no significant difference (80.0% vs 75%, P>0.05), but the 5-year progression-free survival rate of IFN-α and Hydroxyurea therapy groups showed significant difference (86.7% vs 50.0%, P<0.05). After the treatment of IFN-α and HU for six months, the ratio of Interferon-treated patients need to continue phlebotomy was significantly lower than hydroxyurea therapy group (8.3% vs 58.3%, P<0.05). The thromboembolic events,splenomegaly, bone marrow fibrosis of interferon treatment group were lower than hydroxyurea treatment group showed significant difference (P<0.05). The adverse reactions of IFN-α was moderate, most of the patients in this study could tolerate the therapy. The major side effect of hydroxyurea was hematologic adverse reactions (Grade 1-2) with mainly reduce of white blood cells and thrombocytopenia, which showed difference between IFN-α and hydroxyurea (P<0.05). Conclusions IFN-α may improve the prognosis of ET and PV patients with JAK2V617F mutations. Moreover, patients with PV and JAK2V617F mutations may be benefit for the treatment of IFN-α and could be recommended for an effective choice. Disclosures No relevant conflicts of interest to declare." @default.
• W2476753326 created "2016-08-23" @default.
• W2476753326 creator A5009881958 @default.
• W2476753326 creator A5035915037 @default.
• W2476753326 creator A5042449700 @default.
• W2476753326 creator A5043267366 @default.
• W2476753326 creator A5061186599 @default.
• W2476753326 creator A5082251778 @default.
• W2476753326 creator A5085816631 @default.
• W2476753326 date "2014-12-06" @default.
• W2476753326 modified "2023-09-29" @default.
• W2476753326 title "Interferon Alpha May Improve the prognosis of Advanced Myeloproliferative Neoplasm Patients with JAK2V617F Mutations" @default.
• W2476753326 doi "https://doi.org/10.1182/blood.v124.21.5547.5547" @default.
• W2476753326 hasPublicationYear "2014" @default.
• W2476753326 type Work @default.
• W2476753326 sameAs 2476753326 @default.
• W2476753326 citedByCount "0" @default.
• W2476753326 crossrefType "journal-article" @default.
• W2476753326 hasAuthorship W2476753326A5009881958 @default.
• W2476753326 hasAuthorship W2476753326A5035915037 @default.
• W2476753326 hasAuthorship W2476753326A5042449700 @default.
• W2476753326 hasAuthorship W2476753326A5043267366 @default.
• W2476753326 hasAuthorship W2476753326A5061186599 @default.
• W2476753326 hasAuthorship W2476753326A5082251778 @default.
• W2476753326 hasAuthorship W2476753326A5085816631 @default.
• W2476753326 hasConcept C126322002 @default.
• W2476753326 hasConcept C203014093 @default.
• W2476753326 hasConcept C2776178377 @default.
• W2476753326 hasConcept C2776694085 @default.
• W2476753326 hasConcept C2778837598 @default.
• W2476753326 hasConcept C2779316324 @default.
• W2476753326 hasConcept C2779788118 @default.
• W2476753326 hasConcept C2780007613 @default.
• W2476753326 hasConcept C2780076729 @default.
• W2476753326 hasConcept C2781057849 @default.
• W2476753326 hasConcept C2781107747 @default.
• W2476753326 hasConcept C2909179924 @default.
• W2476753326 hasConcept C71924100 @default.
• W2476753326 hasConcept C89560881 @default.
• W2476753326 hasConcept C90924648 @default.
• W2476753326 hasConceptScore W2476753326C126322002 @default.
• W2476753326 hasConceptScore W2476753326C203014093 @default.
• W2476753326 hasConceptScore W2476753326C2776178377 @default.
• W2476753326 hasConceptScore W2476753326C2776694085 @default.
• W2476753326 hasConceptScore W2476753326C2778837598 @default.
• W2476753326 hasConceptScore W2476753326C2779316324 @default.
• W2476753326 hasConceptScore W2476753326C2779788118 @default.
• W2476753326 hasConceptScore W2476753326C2780007613 @default.
• W2476753326 hasConceptScore W2476753326C2780076729 @default.
• W2476753326 hasConceptScore W2476753326C2781057849 @default.
• W2476753326 hasConceptScore W2476753326C2781107747 @default.
• W2476753326 hasConceptScore W2476753326C2909179924 @default.
• W2476753326 hasConceptScore W2476753326C71924100 @default.
• W2476753326 hasConceptScore W2476753326C89560881 @default.
• W2476753326 hasConceptScore W2476753326C90924648 @default.
• W2476753326 hasLocation W24767533261 @default.
• W2476753326 hasOpenAccess W2476753326 @default.
• W2476753326 hasPrimaryLocation W24767533261 @default.
• W2476753326 hasRelatedWork W1618705644 @default.
• W2476753326 hasRelatedWork W1918141746 @default.
• W2476753326 hasRelatedWork W2046294121 @default.
• W2476753326 hasRelatedWork W2361488268 @default.
• W2476753326 hasRelatedWork W2397177319 @default.
• W2476753326 hasRelatedWork W2405701935 @default.
• W2476753326 hasRelatedWork W2419004535 @default.
• W2476753326 hasRelatedWork W2530396170 @default.
• W2476753326 hasRelatedWork W2546588547 @default.
• W2476753326 hasRelatedWork W2548905472 @default.
• W2476753326 hasRelatedWork W2556204412 @default.
• W2476753326 hasRelatedWork W2556673196 @default.
• W2476753326 hasRelatedWork W2564444499 @default.
• W2476753326 hasRelatedWork W2566934960 @default.
• W2476753326 hasRelatedWork W2567109927 @default.
• W2476753326 hasRelatedWork W2580415607 @default.
• W2476753326 hasRelatedWork W2806028933 @default.
• W2476753326 hasRelatedWork W2992945626 @default.
• W2476753326 hasRelatedWork W3032242239 @default.
• W2476753326 hasRelatedWork W910333788 @default.
• W2476753326 isParatext "false" @default.
• W2476753326 isRetracted "false" @default.
• W2476753326 magId "2476753326" @default.
• W2476753326 workType "article" @default.